Kastelein Jacob Pieter Johannes's Insider Trades & SAST Disclosures
Kastelein Jacob Pieter Johannes's most recent trade in NewAmsterdam Pharma Company NV was a trade of 34,000 Ordinary Shares done . Disclosure was reported to the exchange on Jan. 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kastelein Jacob Pieter Johannes.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 34,000 | 34,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 201,673 | 970,229 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 201,673 | 201,673 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 26 Mar 2024 | 190,476 | 0 | - | 21.5 | 4,095,234 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 26 Mar 2024 | 11,197 | 190,476 | - | 22.7 | 254,396 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | Kastelein Jacob Pieter Johannes | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 500,000 | 500,000 | - | - | Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges